Association of Circulating Omega 3, 6 and 9 Fatty Acids with Gestational Diabetes Mellitus: A Systematic Review

shaghayegh hosseinkhani
department of clinical biochemistry,Tehran University of Medical Sciences  https://orcid.org/0000-0003-1258-2581

Hojat Dehghanbanadaki
metabolomics and genomics research center, Tehran university of medical science

Hossein Aazami
endocrinology and genomics research center, Tehran university of medical science

Parvin Pasalar
department of clinical biochemistry,Tehran University of Medical Sciences

Mojgan Asadi
Endocrinology and genomics reasearch center, Tehran university of medical science

Farideh Razi (f-razi@tums.ac.ir)
metabolomics and genomics research center, Tehran university of medical science

Research article

Keywords: Omega fatty acids, Gestational diabetes mellitus, GDM, Maternal lipids, Systematic review

DOI: https://doi.org/10.21203/rs.3.rs-150357/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background: Gestational diabetes mellitus (GDM) is associated with increased risks of disease for mother and child during pregnancy and after that. Early diagnosis of GDM would promote both maternal and fetal health. Metabolomics can simplify and develop our understanding of the etiology, manifestation, or pathophysiology of the disease. This systematic review investigates the association of circulating omega 3, 6, and 9 fatty acids with GDM.

Methods: We conducted a systematic search of PubMed, Scopus, Web of Science and EMBASE databases up to May 8, 2020, using the key term combinations of all types of omega fatty acids with gestational diabetes mellitus. Additional articles were identified through searching the reference lists of included studies.

Results: This systematic review included 14 articles. Four were cohort studies, four included case-control studies and four were case-control studies. Omega fatty acids, as potential biomarkers, are considered to be associated with GDM risk and thus provide useful information regarding the prevention and early diagnosis of GDM. Moreover, existing metabolomic studies on GDM are shown to provide conflicting results about metabolite profile characteristics.

Conclusions: The results of this study demonstrate an increasing trend in the amount of oleic acid and palmitoleic acid in the second trimester and an increase in decosahexanoic acid in the third trimester of GDM mothers. The changes in other fatty acids of interest are either not significant or if significant, their results are inconsistent with the other existing articles.

This systematic review was registered at PROSPERO (www.crd.york.ac.uk/PROSPERO) as CRD42020196122.

Background

Gestational diabetes mellitus (GDM) is a hyperglycemia state that develops or is first recognized during pregnancy. Development of GDM increases the risk for adverse outcomes such as hypoglycemia, respiratory distress syndrome and macrosomia in the newborns, as well as increased risk of cesarean section and development postpartum type 2 diabetes (T2D) in mothers (1). Disparities in race-ethnicity and country of birth are considered to be risk factors for GDM, however, maternal obesity is the strongest risk factor ever known (2). It is also crucial to note that, due to an increasing prevalence of obesity and diabetes mellitus worldwide, the number of pregnant women with GDM is rising.

Altered maternal lipid metabolism in pregnancy with a moderate increase of lipids early in pregnancy and a significant increase of lipids later in pregnancy is also prevalent (2). Studies support primary, narrow, and potentially transitory effects of prenatal long-chain omega 3 polyunsaturated fatty acid (LCn3 PUFAs) amounts on child metabolic status (3). Moreover, the fetal PUFA concentrations and composition essentially depend on the maternal metabolic status because fetal PUFA synthesis is limited and they are transferred to the fetus through the placenta (4). Maternal fatty acid and lipid metabolism change during pregnancy to facilitate fetal growth and development. Adequate amounts of fat is required during pregnancy as both deficiency and excess consumption can have negative effects on fetal as well as maternal health (5). Excessive consumption of fatty foods or imbalance in the consumption of different types of fats, especially omega 3 and omega 6 fatty acids as essential fatty acids and saturated fatty acids, plus changes in fatty acid metabolism during pregnancy can potentially lead to an increased risk for GDM by developing insulin resistance and increasing inflammatory factors. Maternal fatty acid metabolism changes during pregnancy, especially in regards with PUFAs which are reflected in the blood. This matter is considered to be due to insulin resistance in adipose tissues and the release of excess fat into the bloodstream (6). We can get a good interpretation of fatty acid metabolism changes during pregnancy and its relevant complications such as GDM by assessing the concentrations of omega fatty acids during pregnancy is capable of providing us with an excellent interpretation of changes in fatty acid metabolism and other relevant complications, and also gives us the chance to use them as predictors or early diagnostic biomarkers (7).

The metabolomics as a downstream product of gene expression are able to facilitate our understanding of the etiology, manifestation, or pathophysiology of this disease. Compared to biomarkers that are clinically common and diagnostic approaches that are used, Metabolomics also provide proper sensitivity and accuracy. Metabolomics have a promising vision for identifying and measuring considerable metabolic characteristics which lead to pathological conditions like GDM. Studies have employed nuclear magnetic resonance (NMR), targeted or complementary non-targeted gas/liquid chromatography-mass spectrometry (GC/ LC-MS) based assays, etc. to evaluate lipid profiles in GDM (8). Lipidomics studies have led to advances in the structural recognition, classification, and naming of lipids. However, due to the structural and functional complexities of lipids as well as the diversity of their abundance in biological samples, more comprehensive studies with strong methodologies are needed to better understand these compounds (9).

There is a major debate in the literature as to whether lipid patterns differ in women with GDM early in pregnancy and if these early patterns are potential markers of preexisting insulin resistance (2). So, in this study, we intend to systematically investigate the literature to evaluate the omega-3,6 and 9 fatty acid levels in women with GDM, compared to healthy pregnant women based on metabolomic analytical techniques.

Methods

This systematic review is in accordance with the preferred reporting items for the systematic reviews and meta-analysis (PRISMA) statement.

1) Protocol and registration

The systematic review was registered at PROSPERO (www.crd.york.ac.uk/PROSPERO) as CRD42020196122.

2) Eligibility criteria
For the eligible studies, inclusion criteria included: (1) case-control or cohort studies design, (2) comparing the concentration levels of omega 3, 6 and 9 fatty acids in maternal blood, serum, or plasma, (3) participants included pregnant women classified as having GDM and controls (healthy pregnant women with normal glucose tolerance), (4) metabolomic techniques such as GC-MS or NMR spectroscopy were used to measure metabolite profile; and (5) published in English with the full-text articles available.

Exclusion criteria for the articles included: (1) duplicated publications, (2) animal studies, (3) pre-pregnancy diabetes, (4) letters, meta-analyses, reviews, expert opinions, case series, case reports, also articles that did not meet the inclusion criteria were excluded.

3) Information sources & Search

A comprehensive literature search was carried out in the PubMed, Scopus, Web of Science and EMBASE databases to obtain relevant studies and the cut-off date was up to May 8, 2020. In addition, the reference list of all included articles were analyzed carefully to recognize additional articles.

We used the following MeSH terms: "hypogaeic acid" OR "Oleic Acid" OR "elaidic acid" OR gondoic acid OR "mead acid" OR "erucic acid" OR "nervonic acid" OR "ximenic acid" OR "Hexadecatrienoic acid OR "alpha-linolenic acid" OR "stearidonic acid" OR "Eicosatetraenoic acid" OR "Eicosapentaenoic Acid" OR "heneicosapentaenoic acid" "Clupanodonic acid" OR "Docosahexaenoic Acids" OR "Tetracosahexaenoic acid " OR "Tetracosapentaenoic acid" OR "Linoleic Acid" OR "gamma linolenic acid" OR "Calendic acid" OR "Eicosadienoic acid" OR "Eicosadienoic Acid" OR "Arachidonic Acid" OR "Docosadienoic acid" OR "Adrenic acid OR "Tetracosatetraenoic acid OR "tetracosapentaenoic acid" OR AND ("Diabetes, Gestational"[Mesh] OR "Pregnancy-Induced Diabetes" OR "Pregnancy Induced Diabetes" OR "gestational diabetes")

4) Study selection & Data collection process & Data items

Study selection and data collection from all eligible studies were independently evaluated by two investigators. A third person resolved the differences until all reached a set of similar statements. Data on population characteristics and metabolomic techniques and study results were extracted from all eligible studies. Due to the limited number of GDM and metabolic studies, methodological heterogeneity, and considerable differences in the characteristics of the study populations, a quantitative meta-analysis could not be done.

Results

1) Study selection

We identified 703 records from Scopus (n=228), Web of Science (n=117), PubMed (n=90) and EMBASE (n=268) and 1 article identified through manually searching bibliographies; after elimination of duplicates (n=542), 162 records remained. The selection algorithm for the 14 studies that met the inclusion/exclusion criteria for our systematic review is detailed in Fig. 1.

2) Study characteristic

Among the included articles, 10 were original articles and we had access to their full text (10-19) and the other 5 were conference abstracts (20-24).

Five were cohort studies (10, 11, 20, 22, 24), four were nested case-control studies (12, 13, 17, 19) and four were case-control studies (14-16, 18).

All included studies compared metabolites in women with GDM with those in women with normal glucose tolerance (NGT).

The studies used various GDM diagnostic criteria as follows: 5 studies used Carpenter–Coustan criteria (11, 13, 15, 17, 19), 3 studies referenced the International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria (10, 12, 14), 1 study referenced the National Diabetes Data Group criteria (18), 1 study specified using O’Sullivan and Mahan criteria (16), and 5 studies did not specify the GDM diagnostic criteria used (20-24).

The sample size of the GDM study population varied among the studies, ranging from 7 to 305 participants.

The mean age of participants was 32.19 for GDM and 27.02 years for the control group and the mean pre-pregnancy BMI was 27.03 for GDM and 24.04 kg/m² for control group (mean of ages and BMI all studies are reported, except that two studies were conducted on obese women (10, 24)). Accordingly, women who developed GDM had higher BMI and were older than those who didn't.

In 4 articles sampling had taken place in both second and third trimesters (10, 17, 19, 20), 3 articles took samples in the second trimester (11-13) and 4 articles took samples in the third trimester (14-16, 21). There were also 3 articles with sampling in time of delivery (18, 22, 24) and one of the conference abstracts didn't report the time at which sampling had been done (23).

Results have been reported in 2 categories: plasma free omega fatty acids (10 articles) (10-14, 19-21, 23, 24) and plasma phospholipid omega fatty acids (5 articles) (15-18, 22).

9 studies applied GC-MS as an analytical technique (11-13, 15-17, 19-21) and others used NMR (10), LC-MS (23), FIA-MS/MS (14), or liquid-gas chromatography (18).

4 articles had estimated the intake of macronutrients and individual fatty acids during the pregnancy and evaluated the effect of dietary intake on plasma omega fatty acids (11, 15, 16, 19).
Among the evaluated fatty acids, DHA did not change significantly in the second trimester, but in most studies, the third trimester was associated with an increasing trend in this regard. The amount of eicosapentaenoic acid (EPA) measured during pregnancy was generally either increased or did not change significantly. Among the studies conducted in the second trimester, α-Linolenic acid (ALA) did not change significantly and its changes in the third trimester were very contradictory. Changes in omega-6 fatty acids during pregnancy were not significant, if significant, conflicting results were reported. Oleic acid and palmitoleic acid concentrations increased in the second trimester of pregnancy, but their changes in the third trimester were shown to be contradictory.

**Discussion**

**Summary of evidence**

This systematic review summarizes the available data on the association of circulating omega 3, 6, and 9 fatty acids with GDM. Most included studies have revealed correlations between metabolites and GDM risk factors, especially age, pre-pregnancy BMI, family history of T2D, smoking, ethnicity, systolic blood pressure and parity. Just one of the included studies evaluated the frequency of physical activity during pregnancy. Studies mostly used Carpenter–Coustan criteria and then IADPSG criteria as diagnostic criteria. GC-MS was the most applied analytical technique.

Mammals can make saturated and omega-9 monounsaturated fatty acids but are unable to synthesize precursors required to produce omega-3 and omega-6 fatty acids which are needed for the body cells to function properly, so these fatty acids, called essential fatty acids, must be supplied through food. However, mammals can produce some longer-chain unsaturated fatty acids through unsaturation and elongation processes. Linoleic acid as an essential omega-6 fatty acid, is a precursor of dihomogamma linoleic acid, arachidonic acid (20:4 n-6, AA) and α-linoleic acid as an essential omega 3 fatty acid, is a precursor of EPA and docosaeahexenoic acid (DHA) which are their long-chain metabolites (long-chain PUFAs, LC-PUFAs) (27). AA and DHA are important components of the cell membranes. For instance, AA is used in the phospholipid part of the membrane of all cells and DHA is an important part of the phospholipids that make up the membrane of the central nervous system (28). Also, prostaglandins and prostacyclins are among the eicosanoid metabolites of LC-PUFAs that play a key role in placental growth and development, gestational length, and initiation of labor (30).

Pregnancy is associated with changes in the mother's metabolism to provide the fetus' needs for proper growth. This period is associated with increased accumulation of lipids in maternal tissue and the later development of maternal hyperlipidemia (29). During the first months of pregnancy, LC-PUFAs stored in the mother's adipose tissue acts as the only source of LC-PUFAs for fetal growth (30).

**Dietary intake**

Studies conducted on the connection between fatty acids received via dietary and their amounts (that is reflected in blood) revealed that n-3 and n-6 PUFA, in comparison with saturated and monounsaturated fatty acids, have reliable diagnostic worthiness (9). Omega-6 / omega-3 ratio is an important criteria for determining health. A balance in the consumption of omega 3 and 6 fatty acids is necessary to maintain health throughout the lifecycle as well as a successful pregnancy. An imbalance in this ratio leads to auto-immune and mental disorders, chronic inflammation, and diabetes. Over the past few decades, consumption of Western diets which consist of large amounts of omega-6 fatty acids has increased, leading to a loss of fatty acid balance (28). A summary of national nutrition studies shows a reduction in the consumption of PUFAs, especially omega-3 PUFA, derived from seafood on a global scale (9). This issue is important and noteworthy in maintaining the health of people in the community, especially pregnant women who are carriers of the next generation.

**Insulin resistance**

On the other hand, in pregnancy, to ensure the supply of nutrients needed for fetal growth, insulin resistance and hyperinsulinemia can develop to some extent, which in some women leads to gestational diabetes (31). The main pathophysiological causes of GDM are considered to be decreased insulin secretion and abnormal insulin resistance, which are associated with impaired fatty acid metabolism (28).

The amount of fat received through the diet and type of fatty acids that make up the structure of these fats are among the factors that are effective in moderating insulin resistance.

Chen XH et al. reported when HOMA-IR and C-peptide increased, GDM risk has increased by twofold to fourfold. there was a negative relationship between palmitoleic, oleic, linolenic and HOMA-IR and C-peptide levels. In contrast, arachidonic, dihydro-y-linolenic (DGLA) and DHA were positively associated with HOMA-IR and C-peptide (11). As reported by Muñoz-Nava MA et al., HOMA-IR positively correlated with dihydro-gamma linolenic acids, and negatively with oleic and linoleic acids. Beta-cell function in the GDM group positively correlated with linolenic acid and negatively with oleic acid (23). In Zhu YY et al. study, among plasma phospholipid n-3 PUFAs at gestational weeks 10–14, EPA inversely correlated with insulin and HOMA-IR (17).

**Inflammatory markers**

Diabetes is a metabolic disorder caused by increased inflammation. Fatty acids in the diet are among the factors that can affect the inflammatory pathways (32). Adipose tissue has a considerable role in GDM development through synthesis and secretion of a great number of adipocytokines and biologically active materials such as proinflammatory cytokines, acute phase reactants, leptin, resistin, adiponectin and others. These compounds can lead to insulin resistance when synthesized at high levels. There is a basic connection between fatty acids and inflammation, especially as precursors to
eicosanoids as modifiers of inflammation (29). Plasma total antioxidant capacity could be adjusted by the administration of omega-3 fatty acids and vitamin E in women with GDM (34).

In a study by Chen XH et al., cytokine or adipokine levels could be predicted by the individual FFAs. For instance, women with increased DGLA levels were twice as likely to have higher interleukin (IL)-8. Conversely, women who had higher oleic, palmitoleic, and linolenic acid, had decreased odds for having higher interleukin-6 (IL-6), Interleukin-8 (IL-8), or tumor necrosis factor-alpha (TNF-α) (11). Results of a study by Burlina S et al. show that all the inflammatory parameters considered (TNFα, IL6, IL-10 and C-reactive protein) were significantly higher in GDM women than in the NGT group, both during the pregnancy and after delivery (15). In another study by Zhu YY et al., DHA correlated positively with adiponectin, among plasma phospholipid n-3 PUFAs at gestational weeks 10–14 (17).

**BMI**

Pre-pregnancy BMI is a considerable risk factor of GDM by which the risks for developing GDM are 2-6 folds greater in women with either pre-pregnancy obesity or extensive gestational weight gain (GWG) (36). In most obese individuals, elevated Plasma FFA concentrations are observed because extended and stressed adipose cells release more FFA and FFA elimination may be diminished. Moreover, elevated FFA can prevent insulin's antilipolytic action which leads to releasing more FFA into the blood circulation (35). By characterizing the relationship between maternal BMI and GDM with maternal metabolites and neonatal or cord blood metabolites, the theory of the transgenerational cycle of obesity and diabetes can be verified (37).

In a study by White SL et al., it was indicated that obese GDM women exhibited overstated dyslipidemic profiles compared with obese non-GDM women, that integrated the effects of insulin resistance inn the lipid metabolism pathways and subsequently reduced insulin sensitivity from an earlier gestation in pregnant women (10). De La Garza Puentes A et al. reported a BMI ≥ 25 in GDM women with a higher rate of LCn6 to LCn3 fatty acids (22). Wijendran V et al. showed that in women with GDM, Maternal plasma phospholipid DHA and n-3 long-chain PUFAs were significantly lower in overweight (BMI: >25.5 to <30) than in normal-weight (BMI >19.8 to ≤25.5) subjects (16).

**Limitations And Conclusion**

In this study, a part of the included studies were conference abstracts which just reported the significance of results without measuring the levels of omega fatty acids. Among original articles, some of them did not report the concentration levels, and some were reported as fold changes or adjusted results or expressed as a percent of total fatty acids whereas the measures of association were not consistently reported across studies. On the other hand, the amounts of omega fatty acids were measured in various structures such as free in plasma, plasma phospholipids and erythrocyte phospholipids which didn't have enough articles in each subtype, hence impeding meta-analysis.

Although statistically, encouraging progress in the AUC and relation of recognized metabolites in GDM diagnosis and pathogenesis have been observed, there is a need for further investigation in regards of clinical consequences followed by employing these metabolites as predictors of GDM. Advanced findings regarding metabolite disturbances in GDM can be gained by similar investigations that evaluate the abundance of metabolites in more details, incorporate metabolites with clinical characteristics, use multiple platforms, and analyses of various specimen kinds.

Although the amount of fats consumed through food was shown to be in correlation with the amount of free fatty acids circulating in the bloodstream, the impact of dietary intake in most of the studies was not assessed or results presented conflicting relationships. Also, in studies that have measured the effects of diet on blood fatty acids, 24 hour recalls has been used to assess the dietary behaviors. However, it is clear that a 24-hour assessment is not capable of showing a strong correlation between lipid intake and the amount of fatty acid measured in the blood.

It can be one of the strengths of future studies, to design a large characterized study including the assessment of FFAs indices concurrent with insulin resistance or secretion, inflammatory biomarkers which have been accredited and accepted in experimental studies on a large scale. It would be possible to evaluate the distinction potential of the biomarkers by performing the analyses at an early stage of gestation which results in a reliable early diagnosis of GDM. Moreover, evaluation of the necessity of fasting before tests in pregnant women is yet another subject that can be investigated.

This study is the first review to comprehensively and rigorously summarize the available data on the association between circulating omega 3, 6 and 9 fatty acids with GDM and by increasing the number of articles in this field, we will repeat this review by performing a meta-analysis.

**Abbreviations**

Gestational diabetes mellitus (GDM), type 2 diabetes (T2D), normal glucose tolerance (NGT), International Association of Diabetes and Pregnancy Study Groups (IADPSG), α-Linolenic acid (ALA), Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA), Docosahexaenoic acid (DHA), Linoleic acid (LA), Gamma-linolenic acid (GLA), Eicosadienoic acid (EDA), Dihomo-gamma-linolenic acid (DGLA), Arachidonic acid (AA), body mass index (BMI), free fatty acid (FFA), gas chromatography-mass spectrometry (GC-MS), nuclear magnetic resonance (NMR), liquid chromatography-mass spectrometry (LC-MS), flow injection analysis-mass spectrometry (FIA-MS), monounsaturated fatty acid (MUFA), polysaturated fatty acid (PUFA), long-chain polysaturated fatty acid (LC PUFAs), Interleukin-6 (IL-6), Interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-α).

**Declarations**

*Ethics approval and consent to participate*: Not applicable.
Acknowledgements: Not applicable.

References

1. He X, de Seymour JV, Sulek K, Qi H, Zhang H, Han T-L, et al. Maternal hair metabolome analysis identifies a potential marker of lipid peroxidation in gestational diabetes mellitus. Acta diabetologica. 2016;53(1):119-22.

2. Ryckman K, Spracklen C, Smith C, Robinson J, Saftlas A. Maternal lipid levels during pregnancy and gestational diabetes: a systematic review and meta-analysis. BJOG: an international journal of obstetrics & gynaecology. 2015;122(5):643-51.

3. Maslova E, Rifas-Shiman SL, Olsen SF, Gillman MW, Oken E. Prenatal n-3 long-chain fatty acid status and offspring metabolic health in early and mid-childhood: results from Project Viva. Nutrition & Diabetes. 2018;8.

4. Dominguez-Perles R, Gil-Izquierdo A, Ferreres F, Medina S. Update on oxidative stress and inflammation in pregnant women, newborn children (nasciturius), and newborns—Nutritional and dietary effects. Free Radical Biology and Medicine. 2019;142:38-51.

5. Ketin I, Alvino G, Cardellicchio M. Long chain fatty acids and dietary fats in fetal nutrition. The Journal of physiology. 2009;587(14):3441-51.

6. Chavan-Gautam P, Rani A, Freeman D.J. Distribution of fatty acids and lipids during pregnancy. Advances in clinical chemistry. 84: Elsevier; 2018. p. 209-39.

7. Lu L, Koulman A, Petry CJ, Jenkins B, Matthews L, Hughes IA, et al. An unbiased lipidomics approach identifies early second trimester lipids predictive of maternal glycemic traits and gestational diabetes mellitus. Diabetes Care. 2016;39(12):2232-9.

8. Monteiro M, Carvalho M, Bastos M, Guedes de Pinho P. Metabolomics analysis for biomarker discovery: advances and challenges. Current medicinal chemistry. 2013;20(2):257-71.

9. Stark KD. Applications of Innovative Lipidomic Methods for Blood Lipid Biomarkers. Journal of Oleo Science. 2019:ess19042.

10. White SL, Pasupathy D, Sattar N, Nelson SM, Lawlor DA, Briley AL, et al. Metabolic profiling of gestational diabetes in obese women during pregnancy. Diabetologia. 2017;60(10):1903-12.

11. Chen XH, Stein P, Steer RA, Scholl TO. Individual free fatty acids have unique associations with inflammatory biomarkers, insulin resistance and insulin secretion in healthy and gestational diabetic pregnant women. Bjmj Open Diabetes Research & Care. 2019;7(1).

12. Li XP, Huang YC, Xing YL, Hu C, Zhang WX, Tang Y, et al. Association of urinary cadmium, circulating fatty acids, and risk of gestational diabetes mellitus: A nested case-control study in China. Environment International. 2020;137.

13. Enquobahrie DA, Denis M, Tadesse MG, Gelaye B, Ressom HW, Williams MA. Maternal early pregnancy serum metabolites and risk of gestational diabetes mellitus. 2015. p. 4348-56.

14. Lehmann R, Friedrich T, Krebiehl G, Sonntag D, Haring HU, Frütsche A, et al. Metabolic profiles during an oral glucose tolerance test in pregnant women with and without gestational diabetes. Exp Clin Endocrinol Diabetes. 2015;123(7):483-38.

15. Burlina S, Dalfrà MG, Barison A, Marin R, Ragazzi E, Sartore G, et al. Plasma phospholipid fatty acid composition and desaturase activity in women with gestational diabetes mellitus before and after delivery. Acta Diabetologica. 2017;54(1):45-51.

16. Wijendran V, Bendel RB, Couch SC, Philipson EH, Thomsen K, Zhang XF, et al. Maternal plasma phospholipid polyunsaturated fatty acids in pregnancy with and without gestational diabetes mellitus: relations with maternal factors. American Journal of Clinical Nutrition. 1999;70(1):53-61.

17. Zhu YY, Li MY, Rahman ML., Hinkle SN, Wu J, Weir NL, et al. Plasma phospholipid n-3 and n-6 polyunsaturated fatty acids in relation to cardiometabolic markers and gestational diabetes: A longitudinal study within the prospective NICHD Fetal Growth Studies. Plos Medicine. 2019;16(9).

18. Min YJ, Nam JH, Ghebremeskel K, Kim A, Crawford M. A distinctive fatty acid profile in circulating lipids of Korean gestational diabetics: A pilot study. Diabetes Research and Clinical Practice. 2006;73(2):178-83.

19. Chen X, Scholl TO, Leskiw M, Savailev J, Stein TP. Differences in maternal circulating fatty acid composition and dietary fat intake in women with gestational diabetes mellitus or mild gestational hyperglycemia. Diabetes care. 2010;33(9):2049-54.

20. Kumatani S, Daisuke O, Takafulmi Y, Yoshiki T, Maiko W, Osamu T, et al. Longitudinal analysis of relationships between individual fatty acids and gestational diabetes mellitus in maternity log study. Reproductive Sciences. 2019;26:232A-3A.

21. Johansen NJ, Demant M, Suvitaival T, Trost K, Aiken L, Bonde L, et al. Metabolomics reveal changes in plasma concentrations of 3-hydroxybutyric acid, citric acid, oleic acid and proline in gestational diabetes. Diabetologia. 2018;61:S252.
22. De La Garza Puentes A, Bonilla Aguirre M, Dinarés Vancells M, Montes Goyanes R, Chisaguan Toñato AM, Guerendiain ME, et al. Pre-pregnancy body mass index and gestational diabetes on maternal fatty acid profile and placental transfer. Clinical Nutrition. 2016;35:S254-S5.

23. Muñoz-Nava MA, Pérez-Luque EL, Fajardo-Araujo ME, Molina-Torres J, Ramírez-Chávez E, Muñoz-Guevara LM. Serum free fatty acids correlation with the HOMA IR in patients with gestational diabetes. Endocrine Reviews. 2018;39(2).

24. Poole A, Tuvdendorj D, Olson G, Tumurbaatar B, Abate N. A distinct fatty acid profile in obese patients with gestational diabetes. American Journal of Obstetrics and Gynecology. 2015;212(1):S150.

25. Laposata M. Fatty acids: biochemistry to clinical significance. American journal of clinical pathology. 1995;104(2):172-9.

26. Burdge GC, Calder PC. Introduction to fatty acids and lipids. Intravenous Lipid Emulsions. 112: Karger Publishers; 2015. p. 1-16.

27. Cinelli G, Fabrizi M, Ravà L, Ciofi degli Atti M, Vernocchi P, Vallone C, et al. Influence of maternal obesity and gestational weight gain on maternal and foetal lipid profile. Nutrients. 2016;8(6):368.

28. Wadhwani N, Patil V, Joshi S. Maternal long chain polyunsaturated fatty acid status and pregnancy complications. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2018;136:143-52.

29. Herrera E, Desoye G. Maternal and fetal lipid metabolism under normal and gestational diabetic conditions. Hormone molecular biology and clinical investigation. 2016;26(2):109-27.

30. Khaire A, Joshi S. Maternal long-chain polyunsaturated fatty acids and pregnancy outcome. Omega-3 Fatty Acids: Keys to Nutritional Health: Springer International Publishing; 2016. p. 487-99.

31. Silva-Zolezzi I, Samuel TM, Spieldenner J. Maternal nutrition: opportunities in the prevention of gestational diabetes. Nutrition reviews. 2017;75(suppl_1):32-50.

32. Sears B, Perry M. The role of fatty acids in insulin resistance. Lipids in health and disease. 2015;14(1):1-9.

33. Sivan E, Boden G. Free fatty acids, insulin resistance, and pregnancy. Current diabetes reports. 2003;3(4):319-22.

34. Jamilian M, Dizaji SH, Bahmani F, Taghizadeh M, Memarzadeh MR, Karamali M, et al. A randomized controlled clinical trial investigating the effects of omega-3 fatty acids and vitamin E co-supplementation on biomarkers of oxidative stress, inflammation and pregnancy outcomes in gestational diabetes. Canadian journal of diabetes. 2017;41(2):143-9.

35. Boden G. 45Obesity, insulin resistance and free fatty acids. Current opinion in endocrinology, diabetes, and obesity. 2011;18(2):139.

36. Li N, Liu E, Guo J, Pan L, Li B, Wang P & Baccarelli. A A. 2013.

37. Shokry E, Marchioro L, Uhl O, Bermúdez MG, García-Santos JA, Segura MT, et al. Impact of maternal BMI and gestational diabetes mellitus on maternal and cord blood metabolome: results from the PREOBE cohort study. Acta diabetologica. 2019;56(4):421-30.

Tables

Table 1. Characteristics of the Included Studies
| First author/ year | Type of study | country | GDM/ control | age(year) | BMI(kg/m²) | Diagnostic criteria | sample type |
|-------------------|--------------|---------|--------------|----------|-----------|---------------------|-------------|
| White SL 2017     | cohort       | UK      | 198/448      | 31.5 ± 4.6/30.5 ± 5.6 | 36.1 (33.0–39.4)/34.7 (32.6–38.5) | IADPSG       | plasma, serum or whole blood FFAs |
| 2 Chen XH 2019    | cohort       | USA     | 81/1287      | 26.01±6.05/21.90±5.03 | 30.08±6.42/25.37±6.21 | Carpenter/Coustan | plasma FFAs |
| 3 Chen XH 2010    | nested case-control | USA | 49/98       | 25.63 ± 0.81/21.29 ± 0.54 | 30.76 ± 0.93/25.40 ± 0.56 | Carpenter/Coustan | serum FFAs |
| 4 Li XP 2020      | nested case-control | China | 305/305      | 30.6 ± 4.4/30.1 ± 4.1 | 22.4 ± 3.2/20.5 ± 2.6 | IADPSG       | plasma FFAs |
| 5 Enquobahrie DA 2015 | nested case-control | USA | 178/180     | 34.0 ± 4.8/33.1 ± 4.3 | 26.7 ± 7.2/23.4 ± 5.3 | Carpenter/Coustan | Serum FFAs |
| 6 Lehmann R 2015  | case-control | Germany | 9/15        | 32 ± 1/30 ± 1 | 29.8 ± 2.5/25.6 ± 0.8 | IADPSG       | plasma FFAs |
| 7 Burlina S 2016  | case-control | Italy   | 21/21        | 33.9 ± 3.9/33.2 ± 4.6 | 24.6 ± 6.2/22.8 ± 4.0 | Carpenter/Coustan | Plasma phospholipid fatty acids |
| 8 Wijendran V 1999 | case-control | Hartford, CT | 15/15     | 32.13±3.253/29.33±3.99 | 25.95±5.89/23.30±2.98 | O’Sullivan and Mahan | plasma phospholipid fatty acids |
| 9 Zhu YY 2006     | nested case-control | California | 107/214  | 30.5±5.7/30.4±5.4 | - | Carpenter/Coustan | plasma phospholipid fatty acids |
| 10 Min YJ 2006   | case-control | Korea   | 12/12        | 31.5±4.4/28.3±2.8 | 21.4±2.6/21.0±1.7 | National Diabetes Data Group Criteria | plasma phospholipid fatty acids |
| 11 Kumatani S 2019 | cohort       | Japan   | 17/188       | - | - | - | plasma FFAs |
| 12 Johansen NJ 2018 | - | Denmark | 9/6      | 31 ± 6/28 ± 3 | 31.6 ± 6.4/29.7 ± 5.4 | - | plasma FFAs |
| 13 De La Garza Puentes A 2016 | Population based cohort | Spain | 44/135 | - | - | - | plasma phospholipid fatty acids |
| 14 Muñoz-Nava, M. A. 2018 | - | Mexico | 50/50 | - | - | - | serum FFAs |
| 15 Poole A 2015   | cohort       | Galvestone, TX | 7/6     | 33.6±5.9/28.3±5.2 | 41±11.4/38±6.2 | - | serum FFAs |

Table 2. Results of the included studies.
| First author | sampling time (weeks) | w3 FAs | w6 FAs | w9 FAs | analytical technique |
|--------------|----------------------|--------|--------|--------|---------------------|
|              | inc                  | Not.sig| inc    | Not.sig| inc                | dec    | Not.sig |
| 1            | White SL             | 15 - 18| LA     | MUFA   | NMR                |        |        |
|              | 23 - 30              | DHA    |        |        |                    |        |        |
| 2            | Chen XH              | 16     | ALA, EPA, DHA | LA, AA, DGLA | palmitoleic, oleic | GC-MS  |        |
|              | Chen XH              | 15     | EPA    | palmitoleic | GC-MS  |        |
|              | 20-28                | ALA, EPA, DHA | LA, AA | palmitoleic, oleic, Total MUFAs | GC-MS  |        |
| 4            | Li XP                | 13     | EPA, n-3/n-6 ratio | GLA, DGLA | LA, EDA, AA/EPA ratio | AA | hypoigeic acid, oleic acid, Total MUFAs | GC-MS  |        |
| 5            | Enquobahrie DA       | 16     | LA     | Oleic acid | GC-MS  |        |
| 6            | Lehmann R            | 24–27  | AA     |        | FIA-MS/MS          |        |        |
| 7            | Burlina S           | third trimester | ALA, EPA, DPA | LA, DGLA, AA | oleic acid | GC-MS  |        |
| 8            | Wijendran V       | third trimester | DHA, ALA, DPA, EPA | ratio of AA to DGLA | EDA, DGLA | LA, AA | GC-MS  |        |
| 9            | Zhu YY               | 10–14  | DHA, Total n-3 PUFAs | GLA, DGLA | LA, EDA, AA, DTA, n6-DPA |        |        |
|              | 15–26                | EPA, DPA, Total n-3 PUFAs | ALA, DHA, DGLA | EDA, DTA | LA, GLA, AA, n6-DPA |        |        |
| 10           | Min YJ               | delivery | DHA | ALA | Oleic, total MUFA | LA, AA | LC-GC  |        |
| 11           | Kumatani S          | 12-23  | LA     | palmitoleic acid | GC-MS  |        |
|              | 24-34                | LA     | palmitoleic acid | GC-MS  |        |
| 12           | Johansen NJ         | third trimester | EPA, DHA, n3 PUFAs | AA, LC-n6 PUFAs | oleic acid | GC-MS  |        |
| 13           | De La Garza Puentes A | at delivery | EPA, DHA, n3 PUFAs | AA, LC-n6 PUFAs |        |        |        |
|              | Muñoz-Nava, M. A.   | not reported | LA | Oleic acid | LC-MS |        |        |
Abbreviations: increase (inc), decrease (dec), not significant (Not.sig), α-Linolenic acid (ALA), Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA), Docosahexaenoic acid (DHA), Linoleic acid (LA), Gamma-linolenic acid (GLA), Eicosadienoic acid (EDA), Dihomo-gamma-linolenic acid (DGLA), Arachidonic acid (AA), body mass index (BMI), free fatty acid (FFA), gas chromatography-mass spectrometry (GC-MS), nuclear magnetic resonance (NMR), liquid chromatography-mass spectrometry (LC-MS), flow injection analysis-mass spectrometry (FIA-MS), monounsaturated fatty acid (MUFA), polyunsaturated fatty acid (PUFA), long-chain omega 3 polyunsaturated fatty acid (LC-n3 PUFAs), long-chain omega 6 polyunsaturated fatty acid (LC-n6 PUFAs).